Tucidinostat
- Generic Name
- Tucidinostat
- Drug Type
- Small Molecule
- Chemical Formula
- C22H19FN4O2
- CAS Number
- 1616493-44-7
- Unique Ingredient Identifier
- 87CIC980Y0
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Pipeline Progress: Over 25 New Therapies in Development for Metastatic Liver Cancer
• DelveInsight's latest report reveals a robust pipeline with over 20 companies developing 25+ therapies for metastatic liver cancer, offering new hope for patients with limited treatment options.
• Several promising clinical trials are underway in 2025, including studies evaluating novel combinations such as AK104 plus lenvatinib, tislelizumab with lenvatinib, and triplet therapy of nivolumab, relatlimab and bevacizumab.
• Key emerging therapies include exoASO-STAT6 targeting tumor-associated macrophages, STP705 dual TGF-ß1/COX-2 inhibitor, and ONCR-177, an oncolytic viral immunotherapy expressing five transgenes to fight tumors through multiple mechanisms.
Histone Deacetylase Inhibitors Show Promise in Breast Cancer Clinical Trials
• Clinical trials evaluating histone deacetylase (HDAC) inhibitors in breast cancer (BRCA) are underway across 24 regions, with the United States and China leading the efforts.
• The majority of these trials are in early phases (Phase I and II), with Chidamide being the most investigated HDAC inhibitor in BRCA clinical trials.
• Combination therapies involving HDAC inhibitors with hormone therapy, immunotherapy, and targeted therapy are being explored to improve outcomes in BRCA.
• Further research into the mechanisms of HDAC inhibitors is essential to optimize their integration into BRCA treatment strategies and overcome resistance.
HUYABIO's HBI-8000 Plus Nivolumab Shows Promise in Advanced Melanoma
• HUYABIO presented Phase 2 data on HBI-8000 combined with nivolumab for advanced melanoma at the SITC Annual Meeting, revealing encouraging efficacy signals.
• The combination offers an oral treatment option with nivolumab, potentially enhancing efficacy and reducing immune-related toxicities compared to dual checkpoint inhibitors.
• Phase 2 trial results suggest the combination is safe and effective, leading to an ongoing Phase 3 study to further investigate its potential in treating advanced melanoma.
• This novel therapy could expand access to combination therapy for melanoma beyond established markets, especially in areas with limited technical support.
ASC22 and Chidamide Combination Shows Promise in Reducing HIV Reservoir Size
• A Phase II clinical trial evaluated the combination of ASC22, an anti-PD-L1 antibody, and chidamide, a histone deacetylase inhibitor, in HIV-infected adults on ART.
• The study demonstrated a reduction in total and integrated HIV DNA in PBMCs, suggesting a decrease in the HIV reservoir size after 12 weeks of treatment.
• The combination therapy also led to improvements in HIV-specific CD8+ T cell function, indicating enhanced immune control of HIV.
• The treatment was generally well-tolerated, with adverse events monitored throughout the study period.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath